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OBJECTIVE — The purpose of this study was to determine the mechanism by which dipep-
tidyl peptidase-4 inhibitors lower postprandial glucose concentrations.
RESEARCHDESIGNANDMETHODS — Wemeasuredinsulinsecretionandactionas
wellasglucoseeffectivenessin14subjectswithtype2diabeteswhoreceivedvildagliptin(50mg
b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each
period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and -cell
responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At
300 min 0.02 unit/kg insulin was administered intravenously.
RESULTS — Vildagliptin reduced postprandial glucose concentrations (905  94 vs.
1,008104mmol/6h,P0.02).VildagliptindidnotalternetSI(7.711.28vs.6.410.84
10
4 dl   kg
1   min
1   U
1   ml
1, P  0.13) or glucose effectiveness (0.019  0.002 vs.
0.018  0.002 dl   kg
1   min
1, P  0.65). However, the net -cell responsivity index was
increased (35.7  5.2 vs. 28.9  5.2 10
9 min
1, P  0.03) as was total disposition index
(38148vs.2613510
14dl kg
1 min
2 pmol
1 l
1,P0.006).Vildagliptinlowered
postprandial glucagon concentrations (27.0  1.1 vs. 29.7  1.5 g   l
1   6h
1, P  0.03),
especially after administration of exogenous insulin (81.5  6.4 vs. 99.3  5.6 ng/l, P  0.02).
CONCLUSIONS — Vildagliptin lowers postprandial glucose concentrations by stimulating
insulinsecretionandsuppressingglucagonsecretionbutnotbyalteredinsulinactionorglucose
effectiveness. A novel observation is that vildagliptin alters -cell responsiveness to insulin
administration, but the signiﬁcance of this action is as yet unclear.
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G
lucagon-like peptide-1 (GLP-1) is a
peptide hormone produced by the
enteroendocrineLcellsoftheintes-
tinal mucosa and is released in response
to caloric intake. The major form of se-
creted GLP-1, GLP-1-(7,36)-amide, is a
powerful insulin secretagogue that also
suppresses glucagon secretion in a glu-
cose-dependentfashionandmayincrease
insulin action (1). These characteristics
would theoretically make the hormone
ideal therapy for use in type 2 diabetes, a
disorder characterized by defective insu-
lin secretion and action.
However, GLP-1 is rapidly inacti-
vated by dipeptidyl peptidase-4 (DPP-4),
a widely distributed enzyme, which con-
verts the intact peptide to the metabolite
GLP-1-(9,36)-amide. GLP-1–based ther-
apy for type 2 diabetes has required the de-
velopment of GLP-1 receptor agonists such
as exenatide, which are resistant to the ac-
tionofDPP-4,or,alternatively,compounds
thatinhibitDPP-4andtherebyraiseendog-
enous concentrations of active GLP-1 (2).
GLP-1 (3), GLP-1 receptor agonists (4),
and DPP-4 inhibitors (2) all lower post-
prandial glucose concentrations.
GLP-1 and its analogs delay gastric
emptying (5), whereas DPP-4 inhibitors
do not (6), indicating that the effects of
thelatteronpostprandialglucoseconcen-
trations must occur via other mecha-
nisms. It is uncertain whether the lack of
gastrointestinal effects of DPP-4 inhibi-
tors occurs because the resulting rise in
peripheral active GLP-1 concentrations is
not elevated or sustained, in marked con-
trastwithconcentrationsobservedduring
peripheral GLP-1 infusion. Another po-
tential explanation is that DPP-4 inhibi-
tion may alter concentrations of other gut
hormones with effects on appetite or mo-
tility (such as peptide YY), which neutral-
ize the effect of GLP-1 (7). DPP-4
inhibitors, GLP-1, and its analogues de-
crease postprandial glucagon concentra-
tions (2). In contrast with GLP-1 and
GLP-1 receptor agonists, the effect of
DPP-4 inhibition on insulin secretion has
been more uncertain: placebo-controlled
studieshavedemonstratedsimilarinsulin
concentrationsinthepresenceorabsence
of DPP-4 inhibition, despite lower glu-
cose concentrations (6). This result im-
plies that such compounds also increase
insulin secretion for a given glucose con-
centration,ashasbeendemonstratedpre-
viously using model-based parameters of
-cell function (8).
It is possible, however, that these
agents lower postprandial glucose con-
centrationsthroughchangesininsulinac-
tion and glucose effectiveness. The direct
effects of GLP-1 on the ability of glucose
per se to stimulate its own uptake and
suppress its own release (glucose effec-
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but not all (12) studies have suggested
that, when given in pharmacological
doses, GLP-1 increases the ability of insu-
lin and glucose to stimulate glucose up-
take and to suppress glucose production.
Similar controversy exists with regard
to the effects of GLP-1 on insulin action
(9). Given the known differences in
DPP-4 inhibitors, in comparison with
other GLP-1–based therapy, it is possi-
ble that these compounds also differ
withregardtotheirdirecteffectsonglu-
cose metabolism.
To gain greater insight into the mech-
anism(s)bywhichDPP-4inhibitorslower
postprandial glucose concentrations,
we used a randomized, double-blind,
placebo-controlled crossover design in
which subjects received vildagliptin, a
DPP-4inhibitor,orplaceboovera10-day
period. The disposition index, a measure
of insulin secretion for the prevailing in-
sulin action, was measured using the oral
glucose (13) and oral C-peptide minimal
models (14). Glucose effectiveness was
also measured simultaneously. We report
that whereas vildagliptin stimulated insu-
linsecretionandenhancedsuppressionof
glucagon,ithadnoeffectoneitherinsulin
action or glucose effectiveness. Taken to-
gether with previous studies in the same
subjects indicating that vildagliptin does
not alter gastric emptying (6), these data
indicatethatDPP-4inhibitorslowerpost-
prandial glucose concentrations solely by
alterations of islet cell function.
RESEARCH DESIGN AND
METHODS— Afterapprovalfromthe
Mayo Clinic Institutional Review Board,
14subjectswithtype2diabetesgavewrit-
ten informed consent to participate in the
study. All subjects were in good health
and at a stable weight and did not engage
in regular vigorous exercise. Subjects
were not taking medication known to al-
ter gastric emptying such as narcotics or
calcium channel blockers. None of the
subjects had a history of microvascular
complications of diabetes. All subjects
were instructed to follow a weight-
maintenance diet containing 55% carbo-
hydrate,30%fat,and15%proteinforthe
period of study. All oral agents used for
the treatment of diabetes were discontin-
ued 3 weeks before the study.
We used a randomized, double-
blind, placebo-controlled crossover de-
sign. Subjects received either 50 mg
vildagliptin or placebo taken before
breakfast and the evening meal over a 10-
day treatment period with the two treat-
ment intervals being separated by at least
a 2-week washout period. The order of
treatment was random.
SubjectswereadmittedtotheGeneral
Clinical Research Center on the evening
of the 6th day of the treatment period.
Gastricaccommodationwasmeasuredon
the 7th day of the treatment period. The
maximum tolerated volumes of caloric or
noncaloric liquids were measured on the
8th and 10th day of the treatment period
to examine the effect of DPP-4 inhibition
on satiety and postprandial gastrointesti-
nal symptoms. Glucose turnover and
gastric emptying were measured simulta-
neously on the 9th day of the treatment
period; those results have been reported
previously (6). Glucose, insulin, and C-
peptide concentrations measured before
andafteringestionofamixedmealonday
9 and analyzed using the oral and C-
peptideminimalmodelsarethesubjectof
the current report.
In brief, after an 8-h fast, a forearm
vein was cannulated with an 18-gauge
needletoallowinfusionstobeperformed.
An 18-gauge cannula was inserted retro-
gradely into a vein of the dorsum of the
contralateral hand. This was placed in a
heated Plexiglas box maintained at 55°C
to allow sampling of arterialized venous
blood.At180minaprimedcontinuous
infusion of [6,6-
2H2]glucose was initi-
ated. Subjects received the morning dose
(50 mg vildagliptin or placebo) at 30
min. At time 0 subjects consumed a meal
consisting of two scrambled eggs labeled
with 0.75 mCi
99mTc-sulfur colloid, 55g
of Canadian bacon, 240 ml of water, and
Jell-O containing 75 g glucose labeled
with [1-
13C]glucose (4% enrichment).
This provided 510 kcal (61% carbohy-
drate, 19% protein, and 21% fat). An in-
fusionof[6-
3H]glucosewasstartedatthis
time, and the infusion rate varied to
mimictheanticipatedglucoseappearance
of the meal [1-
13C]glucose as described
previously(15).Atthesametime,therate
of infusion of the [6,6-
2H2]glucose was
altered to approximate the anticipated
pattern of fall in endogenous glucose
production (15). Blood was collected at
frequent intervals. To allow a model-
independent assessment of the effect of
vildagliptin on insulin action, 5 hours af-
ter the study start (300 min) subjects re-
ceived 0.02 unit/kg body weight of
insulin intravenously (over a 5-min
period).
Analytical techniques
Plasma samples were placed on ice, cen-
trifuged at 4°C, separated, and stored at
20°C until assayed. Glucose concentra-
tions were measured using a glucose
oxidase method (Yellow Springs Instru-
ments, Yellow Springs, OH). Plasma
insulin was measured using a chemilumi-
nescence assay with reagents (Access As-
say; Beckman, Chaska, MN). Plasma
glucagon and C-peptide were measured
by radioimmunoassay using reagents
supplied by Linco Research (St. Louis,
MO). Sample tubes used for measure-
ment of GLP-1 had 100 mol/l of DPP-4
inhibitor (Linco Research) added. Active
GLP-1 concentrations were measured us-
ing an N-terminal immunoassay supplied
by Linco Research.
Calculations
Netinsulinsensitivity(SI)andnetglucose
effectiveness were measured using the
unlabeled oral minimal model, whereas
the effects of insulin and glucose on glu-
cose disposal were measured with the la-
beled oral minimal model as described
previously (13). -Cell responsivity in-
dexes were estimated from the plasma
glucoseandC-peptideconcentrationsob-
served during the experiment by using
the oral C-peptide minimal model (14),
incorporating age-associated changes in
C-peptide kinetics as measured by Van
Cauteretal.(16).Themodelassumesthat
insulin secretion comprises a static and
dynamic component. The dynamic com-
ponent is likely to represent secretion of
promptly releasable insulin and is pro-
portional to the rate of increase of glucose
concentrations through a parameter,
dynamic, which deﬁnes the dynamic re-
sponsivity index. The static component
represents the provision of new insulin to
thereleasablepoolandischaracterizedby
a static index, static, and by a delay time
constant, T (14). Disposition indexes
werecalculatedasdescribedpreviouslyto
determine the appropriateness of insulin
secretion for the prevailing degree of in-
sulinactionbymultiplying-cellrespon-
sivity indexes (total, dynamic, and static)
by SI.
Statistical analysis
All data are means  SEM. Paired com-
parisons between the treatment and pla-
cebo group were made using a two-way
Student’s t test for paired samples. P 
0.05 was considered to be statistically
signiﬁcant.
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have been reported previously (6).
Brieﬂy, mean age was 53.1  2.0 years,
BMIwas33.91.5kg/m
2,andleanbody
mass was 73.8  2.3 kg. A1C was 6.1 
0.2%. In four subjects diabetes was
treatedwithdietalone,sevensubjectshad
been treated with metformin mono-
therapy, and the remaining three subjects
were treated with a sulfonylurea and met-
formin combination.
Plasma glucose, insulin, C-peptide,
and glucagon concentrations
Administration of vildagliptin resulted in
lowerfastingglucose(7.30.5vs.7.9
0.5 mmol/l,P  0.005), a lower postmeal
peak (14.1  0.6 vs. 15.9  0.9 mmol/l,
P  0.0008), and a lower glycemic area
above basal (905  94 vs. 1,008  104
mmol/6 h, P  0.02) over the duration of
the study (Fig. 1A). Insulin concentra-
tions (Fig. 1B) did not differ when sub-
jects received vildagliptin or placebo
before (54  8 vs. 63  8 pmol/l, P 
0.11) or after (63.1  10.5 vs. 62.1 
10.0 nmol/5 h, P  0.76) meal ingestion.
At300minsubjectsreceived1.470.04
IU of insulin intravenously over a 5-min
period. Subsequent peak insulin concen-
trations did not differ in the presence or
absence of vildagliptin (367  20 vs.
363  36 pmol/l, P  0.92).
C-peptide concentrations (Fig. 1C)
did not differ in the fasting state (0.85 
0.08vs.1.000.12nmol/l,P0.17)or
after meal ingestion (728  60 vs. 746 
75 nmol/6 h, P  0.69). Fasting glucagon
concentrations (Fig. 1D) did not differ
(70.2  3.6 vs. 75.1  5.4 ng/l, P  0.1)
in the presence or absence of vildagliptin.
However, over the ﬁrst 5 h after meal in-
gestion, treatment with vildagliptin re-
sulted in lower postprandial glucagon
concentrations(20.91.6vs.23.71.3
mg/5 h, P  0.03). Intriguingly, insulin
administration (300 min) in the presence
of vildagliptin was associated with sup-
pression of glucagon to a nadir of 81.5 
6.4 vs. 99.3  5.6 ng/l (P  0.02) at
315 min.
Insulin action
Vildagliptin did not alter net insulin ac-
tion(SI7.711.28vs.6.410.8410
4
dl kg
1 min
1 U
1 ml
1,P0.13)
or the effects of insulin on glucose dis-
posal (4.37  0.98 vs. 4.83  1.14 dl  
kg
1   min
1   U
1   ml
1, P  0.53).
The effect of exogenous insulin on glu-
cose concentrations over the last hour of
the study was used as a model-
independent estimate of insulin action.
The change in glucose concentrations
over the last hour of the study, after insu-
lin administration, did not differ
(0.75  0.3 vs. 1.0  0.25 mmol/l,
P  0.22) in the presence or absence of
vildagliptin (Fig. 1A).
Glucose effectiveness
Vildagliptin (Fig. 2, top panel) did not al-
ter net glucose effectiveness, measured
using the unlabeled oral minimal model
(0.019  0.002 vs. 0.018  0.002 dl  
kg
1 min
1,P0.65),or(Fig.2,bottom
panel)theeffectofglucoseonglucosedis-
posal, measured with the labeled oral
minimal model (0.011  0.001 vs.
0.010  0.001 dl   kg
1   min
1, P 
0.40).
Insulin secretion and disposition
indexes
Vildagliptin increased dynamic (817 
208 vs. 621  184 10
9, P  0.14) (Fig.
2, top left panel), although this difference
was not signiﬁcant. On the other hand,
static (30.4  4.3 vs. 24.5  4.2 10
9
min
1,P0.03)(Fig.2,centerleftpanel)
and total (35.7  5.2 vs. 28.9  5.2
10
9 min
1, P  0.03) (Fig. 2, bottom left
panel) were signiﬁcantly increased com-
pared with placebo. Expressing these in-
dexes as a function of prevailing insulin
action (disposition index [DI]) demon-
strated (Fig. 2, top, center, and bottom right
panels) increased insulin secretion in the
presence of vildagliptin compared with
placebo for DIdynamic (8,654  1,335 vs.
5,904  1,513 10
14 dl   kg
1   min
1  
pmol
1   l
1, P  0.02), DIstatic (324.2 
40.7 vs. 219.0  24.6 10
14 dl   kg
1  
min
2   pmol
1   l
1, P  0.007), and
DItotal (381  48 vs. 261  35 10
14 dl  
kg
1   min
2   pmol
1  l
1, P  0.006).
As we reported previously (6), fasting
concentrationsofactiveGLP-1(3.71.0
vs. 3.8  1.1 pmol/l, P  0.68) did not
differ between groups. After meal inges-
tion, in the presence of vildagliptin, con-
centrationsrose(11.82.0vs.5.80.8
pmol/l, P  0.01) and remained elevated
for the duration of the study as shown by
theareaunderthecurve(2,224330vs.
1,527  376 pmol   l
1   6h
8, P 
0.001).
CONCLUSIONS — The present
studies indicate that DPP-4 inhibitors in-
crease insulin secretion and suppress glu-
cagonconcentrations.Incontrast,theydo
notalterhepaticinsulinclearance,insulin
action, or glucose effectiveness. Taken to-
gether with the previous report in the
same subjects indicating that DPP-4 in-
hibitors do not alter gastric emptying (6),
these data demonstrate that DPP-4 inhib-
itors lower postprandial glucose concen-
trations solely by altering - and -cell
function.
TheeffectsofGLP-1oninsulinaction
are controversial. Some, but not all, stud-
ies suggest that GLP-1, when given at
pharmacological concentrations, directly
enhances glucose uptake and suppresses
glucose production (9). The present data
indicate that short-term (9 days) inhibi-
tionofDPP-4doesnotalterinsulinaction
in individuals with type 2 diabetes. Insu-
lin action was measured using the labeled
andunlabeledoralminimalmodel.Inad-
dition, the changes in glucose concentra-
tion over the last hour of the study after
insulininjectiondidnotdifferinthepres-
ence or absence of vildagliptin. Vildaglip-
tin was only administered for 9 days
before the experiment, raising the possi-
bility that an effect on insulin action
mighthavebeenobservedwithlongerpe-
riods of administration. Such an experi-
ment would, however, have to account
forthepossibilitythatimprovedglycemic
control per se might improve insulin ac-
Figure 1—Glucose, insulin, C-peptide and
glucagon concentrations in the presence and
absence of vildagliptin.
Vildagliptin, insulin secretion, and action
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term administration of DPP-4 inhibitors
does not lower postprandial glucose con-
centrations by increasing insulin action.
Our experiment differs from a re-
cently published study (17) that used a
similar double-blind, placebo-controlled,
crossover design. However, vildagliptin
(or placebo) was administered over a 42-
day period. Insulin action was measured
using a two-step insulin infusion-glucose
clamp. Under euglycemic hyperinsuline-
mic conditions a slight, but signiﬁcant,
increase in glucose disposal in the pres-
enceofvildagliptinwasobserved.Thisre-
sult implies that vildagliptin improves
insulin action in individuals with type 2
diabetes. A potential explanation for this
discrepancy is that improved glycemic
control associated with DPP-4 inhibition
alleviates glucose toxicity (18) or lipotox-
icity (17), phenomena more likely to oc-
cur over an extended rather than a brief
period of administration. Another possi-
ble explanation is that the greater impre-
cision of the model-dependent para-
meters of insulin action and the smaller
sample size of our study meant that we
were unable to detect a small change in SI
produced by vildagliptin.
Some (10,11), but not all (12), previ-
ous reports have suggested that GLP-1
can improve glucose effectiveness. The
present data indicate that DPP-4 inhibi-
torsdonotimproveglucoseeffectiveness.
As with insulin action, glucose effective-
ness was measured using both the unla-
beled and labeled oral minimal models.
Theunlabeledmodelmeasuresthenetef-
fect of glucose on suppression of glucose
production and stimulation of glucose
uptake. In contrast, the labeled minimal
model only measures the ability of glu-
cose to enhance its own uptake. Neither
was altered by short-term treatment with
vildagliptin. Therefore, as is the case for
insulin action, vildagliptin-mediated en-
hancement of glucose effectiveness can-
not account for the lower postprandial
glucose concentrations observed with
DPP-4 inhibitors.
DPP-4 inhibition improved insulin
secretion both when measured as global
secretion (total) or relative to insulin ac-
tion(dispositionindex).Theincreasewas
due to an increase in static (a measure of
insulin secretion at a given glucose con-
centration) as well as to an increase in
dynamic(ameasureofinsulinsecretionin
response to changing glucose concentra-
tions). A prior experiment speciﬁcally de-
signedtocomparetheeffectoforalversus
intravenous glucose on the -cell respon-
sivity to glucose in healthy subjects
showed that oral glucose delivery in-
creased both the static and the dynamic
indexes of insulin secretion (19). These
results suggested that incretins modulate
multiple steps in the process of insulin
secretion in healthy subjects. Likewise, in
this experiment the use of a DPP-4 inhib-
itor resulted in improvements in both
static and dynamic indexes of insulin se-
cretion despite relatively small changes in
incretin concentrations in the presence of
vildagliptin (6). DPP-4 inhibition seems
to improve multiple defects in the insulin
secretory cascade (secretory granule
priming or docking) in individuals with
type 2 diabetes. These data are consistent
with the previous reports examining the
effect of DPP-4 inhibition on insulin se-
cretioninindividualswithtype2diabetes
(8,17,20–23).
Defectivepostprandialsuppressionof
glucagon is an important contributor to
postprandial hyperglycemia in individu-
als with type 2 diabetes (24), especially in
thepresenceofdefectiveinsulinsecretion
(25). Consistent with previous studies
(17), postprandial glucagon concentra-
tions were lower in the presence of vilda-
gliptin. This lowering could occur via
multiple mechanisms including a direct
effect of GLP-1 on -cells, increased so-
matostatin secretion by islet 	-cells, or in-
creased islet insulin concentrations.
However, in this study we observed a
noveleffectofinsulininjectionatthestart
of the ﬁnal hour of the study. This injec-
tion was given to derive a model-
independent measurement of insulin
action. Surprisingly, in the presence of
vildagliptin, it was accompanied by a
greater suppression of glucagon than in
the absence of DPP-4 inhibition, which
occurred in every subject studied. Thus,
this observation is unlikely to be due to
chance alone. Glucose concentrations
werevirtuallyidenticalat300min,imply-
ing that inhibition of DPP-4 and the
changes produced in incretin concentra-
tions enhance the ability of insulin to di-
rectly suppress glucagon release. Further
studies will be required to determine the
mechanismbywhichthissuppressionoc-
curs, but this ﬁnding implies that incre-
tin-induced increases in insulin secretion
will result in an even greater suppression
of glucagon release than would be ob-
served for a comparable increase of in-
traislet insulin in the absence of DPP-4
inhibition.
In summary, vildagliptin lowers glu-
cose concentrations through its effects on
insulin and glucagon secretion. In this
study we also demonstrate through mod-
eling and model-independent methodol-
ogy that vildagliptin has no direct effect
on insulin action to increase glucose uti-
lizationordecreaseglucoseproduction.A
novel observation is that vildagliptin al-
ters -cell responsiveness to insulin ad-
ministration, but the mechanism and
Figure2—-Cellresponsivity(Phi)anddispositionindexes(DI)inthepresence(f)andabsence
( ) of vildagliptin. *P  0.05.
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